Malignant Adenoma Clinical Trials
A listing of Malignant Adenoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 7 clinical trials
UPCC 35217: A Phase 1B/2 Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.
- 0 views
- 19 Feb, 2024
- 1 location
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 28218: A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Treatment will consist of nivolumab every 4 weeks and ipilimumab every 8 weeks until disease progression, unacceptable toxicity, or 2 years …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 23220 Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
This research study consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be …
- 0 views
- 19 Feb, 2024
- 1 location
Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Pancreatic Cancer
This is a pilot study in patients with histologically proven pancreatic adenocarcinoma who have demonstrated at least stable disease following at least 16 weeks of treatment with platinum-based chemotherapy and are recommended for treatment with a PARP inhibitor with or without additional agents, either as part of their clinical care …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 10518: An Open Label Single Arm Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post PD 1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma
The primary purpose of this study is to gain information about the safety and activity of grapiprant when taken with pembrolizumab in patients who have actively growing or spreading type of advanced stage lung cancer called non-small cell lung cancer (NSCLC).
- 0 views
- 19 Feb, 2024
- 1 location